Verrica Pharmaceuticals
VRCA
64 hedge funds and large institutions have $132M invested in Verrica Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 11 closing their positions.
125% more capital invested
Capital invested by funds: $58.5M → $132M (+$73.3M)
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
0.7% more ownership
Funds ownership: 3.58% → 4.28% (+0.7%)
4% less funds holding
Funds holding: 67 → 64 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
66% less call options, than puts
Call options by funds: $209K | Put options by funds: $620K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$8.47M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$4.3M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$444K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$351K |
| 5 |
BlackRock
New York
|
+$348K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
-$1.01M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$649K |
| 3 |
Renaissance Technologies
New York
|
-$265K |
| 4 |
Two Sigma Investments
New York
|
-$251K |
| 5 |
Millennium Management
New York
|
-$110K |
VRCA Hedge Fund Activity: Q4 2023 in Review
64 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q4 2023, worth a combined $132M — up 125% from $58.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VRCA and 8 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 23 added.
The largest buyer was Perceptive Advisors, adding an estimated $8.47M. The largest seller was Caligan Partners, exiting entirely with an estimated $1.01M sold.
- 64 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q4 2023, down from 67 in Q3 2023.
- Funds reported $132M of Verrica Pharmaceuticals stock for Q4 2023, up 125% quarter-over-quarter.
- 8 funds opened new Verrica Pharmaceuticals positions in Q4 2023 and 11 closed out, a net change of -3 holders.
- The largest Verrica Pharmaceuticals buyer in Q4 2023 was Perceptive Advisors, an estimated $8.47M added.
- The largest Verrica Pharmaceuticals seller in Q4 2023 was Caligan Partners, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2023.